-
Get the latest information and research on osteoporosis.
-
Find treatment, guidance and advice on living with osteoporosis.
-
Share your experience and get involved. Joining the conversation is the first step to ending osteoporosis and broken bones.
Following is a statement by the National Osteoporosis Foundation on Bone Mineral Density Testing
WASHINGTON, DC (January 20, 2011) — The National Osteoporosis Foundation (NOF) recommends a comprehensive approach to the diagnosis and management of osteoporosis. A detailed history and physical examination together with Bone Mineral Density (BMD) assessment and, where appropriate, the WHO 10-year estimated fracture probability are utilized to establish the individual patient’s fracture risk. The potential risks and benefits of all osteoporosis interventions should be reviewed with patients and the unique concerns and expectations of individual patients considered in any final therapeutic decision.
Utilizing any procedure to measure bone density is not indicated unless the results will influence the patient’s treatment decision. NOF recommends testing of all women age 65 and older. NOF also recommends testing of men age 70 and older. BMD measurement is not recommended in children or adolescents and is not routinely indicated in healthy young men or premenopausal women.
In accordance with NOF’s Clinician’s Guide, the following are NOF’s indications for BMD Testing:
- Women age 65 and older and men age 70 and older, regardless of clinical risk factors
- Younger postmenopausal women and men age 50 to 69 about whom you have concern based on their clinical risk factor profile
- Women in the menopausal transition if there is a specific risk factor associated with increased fracture risk such as low body weight, prior low-trauma fracture or high risk medication
- Adults who have a fracture after age 50
- Adults with a condition (e.g., rheumatoid arthritis) or taking a medication (e.g., glucocorticoids in a daily dose ≥ 5 mg prednisone or equivalent for ≥ three months) associated with low bone mass or bone loss
- Anyone being considered for pharmacologic therapy for osteoporosis
- Anyone being treated for osteoporosis, to monitor treatment effect
- Anyone not receiving therapy in whom evidence of bone loss would lead to treatment
- Postmenopausal women discontinuing estrogen should be considered for bone density testing
To view NOF’s Clinician’s Guide, please click here and to view NOF’s Bone Basics on Bone Mineral Density Testing, click here.
The latest
The National Osteoporosis Foundation has named Barbara Hannah Grufferman as its first Bone Health Ambassador. In this newly-established role, Grufferman, a well-known advocate for healthy and positive living, will dedicate her time, talent and energy to raise awareness for osteoporosis and the importance of building strong bones for life.
Thanks to a generous gift from The Samuel J. & Ethel LeFrak Charitable Trust, the National Osteoporosis Foundation met its Generations of Strength fundraising goal one year early. NOF launched the Generations of Strength initiative in September 2011 with the goal of raising $2 million in two years to improve patient care for the most vulnerable – those who have broken bones due to osteoporosis – and to protect future generations from the disease.
The National Osteoporosis Foundation (NOF), the nation’s leading health organization dedicated to preventing osteoporosis and broken bones, has named Claire Gill as its Senior Director of Marketing, Consumer and Corporate Outreach. Gill brings extensive experience in public relations and marketing communications to this newly-established role.
